

English
-
-
Similarities and differences between 'cytokine storms’ in acute dengue and COVID-19
Takeda2 minutes -
Dengue: Not Just 1 Virus, Not Just 1 Infection
Medscape15 minutes -
Antibody Levels over Time
Takeda2 minutes -
Immune response to dengue virus
Takeda4 minutes -
Dengue virus and pathobiology
Takeda1 minutes -
NS1 and its potential association with severe dengue
Takeda3 minutes -
Dengue - unanswered scientific questions
Takeda11 minutes -
Dengue serotypes
Takeda4 minutes -
Combination of inflammatory and vascular markers in the febrile phase of dengue is associated with more severe outcomes
Takeda2 minutes -
A fatal case report of antibody-dependent enhancement of dengue virus type 1 following remote Zika virus infection
Takeda2 minutes -
Coagulation abnormalities in Dengue fever infection: A systematic review and meta-analysis
Takeda2 minutes -
Distinct Dengue Epidemiology and Viral Characteristics in Indonesia
ADVA25 minutes -
Dengue Virus Life Cycle
HHMI BioInteractive4 minutes -
Dengue disease awareness
ISID39 minutes -
Case presentations in severe dengue: contemporary approaches to clinical management
Medscape45 minutes -
Managing the severely ill dengue patients – Adult and Paediatric Intensivists
ADVA92 minutes -
Effects of dengue
Takeda7 minutes -
Zika and dengue but not chikungunya are associated with Guillain–Barré syndrome in Mexico: A case-control study
Takeda2 minutes
Dengue Academy is intended for an international audience of healthcare professionals outside of the US and UK.
This website has been initiated and developed by Takeda
© Copyright 2025 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.
VV-MEDMAT-55340, Date of preparation: November 2023